Nanoparticle paves the way for new triple negative breast cancer drug

March 16, 2017, University of Bradford
Professor Mohamed El-Tanani, Institute for Cancer Therapeutics, University of Bradford, UK. Credit: University of Bradford

A potential new drug to tackle the highly aggressive 'triple negative' breast cancer - and a nanoparticle to deliver it directly into the cancer cells - have been developed by UK researchers.

The is a peptide (fragment of a protein) discovered by Professor Mohamed El-Tanani at the University of Bradford's Institute for Cancer Therapeutics. Professor El-Tanani has shown in computer models that the peptide blocks a protein called RAN which helps cancer cells to divide and grow. High levels of RAN have been linked to aggressive tumour growth, cancer spread, resistance to chemotherapy and poor prognosis in a number of cancers, including triple negative breast cancer (TNBC).

"We knew we'd need a novel delivery mechanism for this drug because on their own are unstable and they can degrade too quickly to be effective," explains Professor El Tanani. "Using a nanoparticle as a delivery mechanism was the perfect solution."

Working with colleagues from Ulster University, Sunderland and Queen's University Belfast, the team developed a nanoparticle from a biodegradable polymer that could encapsulate the peptide. They tested various different polymers in order to determine which was most effective at helping the protein enter the cancer cells and attack them.

Laboratory tests showed that when this nanoparticle, loaded with the peptide, was added to the triple negative , the cells would actively take it in. Their growth rate then reduced, they stopped replicating and around two thirds of the cells died within 24 hours. This compared with the peptide on its own, or an empty nanoparticle, which had no impact on the cells' growth.

The researchers also confirmed that the drug was killing the cancer cells through the mechanism they had seen in their computer models - by blocking the action of RAN which plays an important role in cell division and growth.

Previous research by Professor El-Tanani has shown that blocking RAN can also prevent or even reverse resistance to chemotherapy in small cell lung cancer.

Between 10-20 per cent of breast cancers are found to be triple negative - which means the cancer does not have receptors for the hormones oestrogen and progesterone or the protein HER2. This limits the range of treatments that can be used, resulting in poorer prognosis and increased risk of recurrence.

"By developing a nanoparticle that can help this peptide enter triple negative breast and block RAN we've brought this potential new treatment a step closer to the clinic," said Professor El-Tanani. "We're already working on in vivo tests of the nanoparticle in a triple negative model and are thinking ahead to taking this drug into clinical trials."

Professor El-Tanani is also working on a number of other potential RAN inhibitors, including a 'repurposed' drug that has been already pre-clinically validated in breast and lung cancer and is ready for clinical trials. The University of Bradford is actively seeking further funding and investor support to support the development of these drug candidates.

The findings are published in the International Journal of Pharmaceutics.

Explore further: Blocking Ran protein reverses resistance of lung and breast cancers

More information: Yusuf A. Haggag et al, Nano-encapsulation of a novel anti-Ran-GTPase peptide for blockade of regulator of chromosome condensation 1 (RCC1) function in MDA-MB-231 breast cancer cells, International Journal of Pharmaceutics (2017). DOI: 10.1016/j.ijpharm.2017.02.006

Related Stories

Blocking Ran protein reverses resistance of lung and breast cancers

October 4, 2016
Researchers at the University of Bradford have discovered a way to prevent chemotherapy resistance in lung cancer by blocking a protein found in cancer cells.

Promising findings towards targeted breast cancer therapy

November 14, 2016
New research led by Conway Fellow, Professor Joe Duffy and Professor John Crown in St Vincent's University Hospital has reported for the first time on a new treatment that could be used in the majority of patients with triple ...

Discovery of potential treatment for aggressive form of breast cancer

November 2, 2016
A new drug could be used to treat one of the most aggressive forms of breast cancer, a research centre based at University College Dublin and St Vincent's Hospital has discovered.

Researchers identify new potential treatment for cancer metastasis

January 9, 2017
Breast cancer metastasis, the process by which cancer spreads, may be prevented through the new use of a class of drugs already approved by the U.S. Food and Drug Administration.

Natural compound found in herbs, vegetables could improve treatment of triple-negative breast cancer in women

January 23, 2017
More than 100 women die from breast cancer every day in the United States. Triple-negative breast cancers, which comprise 15 to 20 percent of all breast tumors, are a particularly deadly type of breast disease that often ...

The way breast cancer genes act could predict your treatment

February 21, 2017
A Michigan State University breast cancer researcher has shown that effective treatment options can be predicted based on the way certain breast cancer genes act or express themselves.

Recommended for you

Researchers discover new anti-cancer protein

March 21, 2018
An international team of researchers has discovered a new anti-cancer protein. The protein, called LHPP, prevents the uncontrolled proliferation of cancer cells in the liver. The researchers led by Prof. Michael N. Hall from ...

Targeting telomeres to overcome therapy resistance in advanced melanoma

March 21, 2018
A study conducted at The Wistar Institute in collaboration with The University of Texas Southwestern Medical Center has demonstrated the efficacy of targeting aberrantly active telomerase to treat therapy-resistant melanoma. ...

Cancer comes back all jacked up on stem cells

March 19, 2018
After a biopsy or surgery, doctors often get a molecular snapshot of a patient's tumor. This snapshot is important - knowing the genetics that cause a cancer can help match a patient with a genetically-targeted treatment. ...

Researchers create a drug to extend the lives of men with prostate cancer

March 16, 2018
Fifteen years ago, Michael Jung was already an eminent scientist when his wife asked him a question that would change his career, and extend the lives of many men with a particularly lethal form of prostate cancer.

Machine-learning algorithm used to identify specific types of brain tumors

March 15, 2018
An international team of researchers has used methylation fingerprinting data as input to a machine-learning algorithm to identify different types of brain tumors. In their paper published in the journal Nature, the team ...

Higher doses of radiation don't improve survival in prostate cancer

March 15, 2018
A new study shows that higher doses of radiation do not improve survival for many patients with prostate cancer, compared with the standard radiation treatment. The analysis, which included 104 radiation therapy oncology ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.